Clinical Trials Browser

encorafenib × 90 days × Clear all

NCT04074096 2026-06-05

BEPCOME-MB

Phase 2 Active not recruiting

CNSDermatologic

Brain Neoplasms, Melanoma

NCT04800822 2026-06-04

PF-07284892 in Participants With Advanced Solid Tumors

Phase 1 Terminated

CNSGastrointestinalThoracic

Carcinoma, Non-Small-Cell Lung, Neurofibromatosis 1, Hereditary Sensory and Autonomic Neuropathies, Colorectal Neoplasms

NCT05576896 2026-06-04

Hydroxychloroquine in Combination With Encorafenib and Cetuximab or Panitumumab in the Treatment of Metastatic BRAF-mutated Colorectal Cancer Refractory

Phase 2 Active not recruiting

Gastrointestinal

Colorectal Neoplasms

NCT05308446 2026-06-03

Testing the Addition of Nivolumab to Standard Treatment for Patients With Metastatic or Unresectable Colorectal Cancer That Have a BRAF Mutation

Phase 2 Active not recruiting

Gastrointestinal

Colonic Neoplasms, Rectal Neoplasms

NCT06102902 2026-06-03

Testing the Addition of Anti-cancer Drug, ZEN003694, to the Usual Chemotherapy Treatment, Cetuximab Plus Encorafenib, for Colorectal Cancer

Phase 1 Suspended

Gastrointestinal

Colorectal Neoplasms

NCT03693170 2026-05-29

ANCHOR-CRC

Phase 2 Completed

95 enrolled 30 charts

Gastrointestinal

Colorectal Neoplasms

NCT04221438 2026-05-29

Testing Treatment With Encorafenib and Binimetinib Before Surgery for Melanoma With Lymph Node Involvement

Phase 2 Terminated

3 enrolled 11 charts

Lymphatic Metastasis, Melanoma

NCT04017650 2026-05-22

Encorafenib, Cetuximab, and Nivolumab in Treating Patients With Microsatellite Stable, BRAFV600E Mutated Unresectable or Metastatic Colorectal Cancer

Phase 1/2 Active not recruiting

Gastrointestinal

Colonic Neoplasms, Rectal Neoplasms, Colorectal Neoplasms, Disease Progression

NCT05615818 2026-05-19

SAFIR-ABC10

Phase 3 Recruiting

Gastrointestinal

Biliary Tract Neoplasms

NCT03803553 2026-05-01

Identification and Treatment Of Micrometastatic Disease in Stage III Colon Cancer

Phase 3 Recruiting

Gastrointestinal

Colonic Neoplasms

NCT05195632 2026-05-01

OCEANII

Phase 2 Active not recruiting

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

NCT05004350 2026-04-30

NAUTICALCRC

Phase 2 Completed

107 enrolled 69 charts

Gastrointestinal

Colorectal Neoplasms

NCT07092410 2026-04-21

SuRage-EB

Phase 4 Withdrawn

Melanoma

NCT05026983 2026-04-16

Binimetinib and Encorafenib for the Treatment of Metastatic Melanoma and Central Nervous System Metastases

Phase 2 Recruiting

Melanoma

NCT04061980 2026-04-13

Encorafenib and Binimetinib With or Without Nivolumab in Treating Patients With Metastatic Radioiodine Refractory BRAF V600 Mutant Thyroid Cancer

Phase 2 Active not recruiting

Thyroid Neoplasms

NCT07022457 2026-04-13

UK-EnBiRiM

Active not recruiting

Melanoma

NCT04657991 2026-04-07

A Clinical Trial of Three Study Medicines (Encorafenib, Binimetinib, and Pembrolizumab) in Patients With Advanced or Metastatic Melanoma

Phase 3 Active not recruiting

Melanoma, Skin Neoplasms

NCT05203172 2026-04-07

The FLOTILLA Study: Providing Continued Access to The Study Medicines Encorafenib and Binimetinib for Participants in Prior Clinical Trials

Phase 4 Recruiting

Other solid neoplasm

Solid Tumors

NCT05217446 2026-04-07

SEAMARK

Phase 2 Active not recruiting

Gastrointestinal

Colonic Neoplasms, Rectal Neoplasms, Colorectal Neoplasms

NCT04324112 2026-03-31

Encorafenib Plus Binimetinib for People With BRAF V600 Mutated Relapsed/Refractory HCL

Phase 2 Recruiting

Other hematologic neoplasm

Leukemia, Hairy Cell

NCT05039177 2026-03-25

HERKULES-3

Phase 1/2 Completed

Gastrointestinal

Digestive System Neoplasms, Gastrointestinal Neoplasms, Pancreatic Neoplasms, Colorectal Neoplasms

NCT03915951 2026-03-24

An Open-label Study of Encorafenib + Binimetinib in Patients With BRAFV600-mutant Non-small Cell Lung Cancer

Phase 2 Completed

98 enrolled 18 charts 1 FDA

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms, Neoplasms